



Innovate in India for Inclusiveness (P156241)

SOUTH ASIA | India | Finance, Competitiveness and Innovation Global Practice |
IBRD/IDA | Investment Project Financing | FY 2017 | Seq No: 8 | ARCHIVED on 27-Aug-2021 | ISR47943 |

Implementing Agencies: India, Biotechnology Industry Research Assistance Council

Key Dates

Key Project Dates

Bank Approval Date: 31-May-2017

Effectiveness Date: 23-May-2018

Planned Mid Term Review Date: 07-Oct-2020

Actual Mid-Term Review Date: 26-Oct-2020

Original Closing Date: 30-Jun-2023

Revised Closing Date: 30-Jun-2023

Project Development Objectives

Project Development Objective (from Project Appraisal Document)

The proposed project development objective (PDO) is to facilitate innovation in biopharmaceutical products and medical devices that address public health priorities in India

Has the Project Development Objective been changed since Board Approval of the Project Objective?

No

Components Table

Name
Strengthening the pilot-to market innovation ecosystem:(Cost \$125.00 M)
Accelerating the pilot-to-market process for specific products:(Cost \$120.00 M)
Project management:(Cost \$5.00 M)

Overall Ratings

Name	Previous Rating	Current Rating
Progress towards achievement of PDO	<input type="checkbox"/> Satisfactory	<input type="checkbox"/> Satisfactory
Overall Implementation Progress (IP)	<input type="checkbox"/> Moderately Satisfactory	<input type="checkbox"/> Moderately Satisfactory
Overall Risk Rating	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial

Implementation Status and Key Decisions

The project is making satisfactory progress in achieving its project development objective (PDO). All five PDO indicators have achieved end of project targets: 32 intellectual property (IP) registrations or product prototypes, 13 technologies licensed for manufacturing or commercialization, 50 products that address public health priorities advancing at least one step on the product development pathway, 7 technology transfer offices established, and 108 companies using the shared facilities supported by the project.

Project support in response to COVID-19 is advancing. The project is supporting the development of six novel COVID vaccine candidates (e.g., DNA, Adenovirus, Virosome, Subunit). A vaccine supported during Phase I/II trials, Zydus Cadila, received emergency approval on August 20, becoming the world's first approved DNA vaccines. The Biological E vaccine recently completed Phase II for all 360 subjects. In addition, two vaccine candidates have moved to Phase III clinical trials. In addition, the cGMP manufacturing facility at Shilpa Biologicals is now manufacturing the drug substance for the Sputnik-V vaccine. Similarly, manufacturing facilities have developed RT-PCR Diagnostic Kits for detection of COVID-19 infection, Ventilators, Nucleic Extraction Kits, Material and Viral Transfer Medium, and Pulse Oximeters.



Project implementation is also making progress with over 92 percent of project funds committed in INR. Disbursement, currently at 32 percent, is below the agreed targets. The COVID-19 pandemic has affected the ability of beneficiaries to implement their projects, especially as most of the work requires physical presence (e.g. laboratories).

Risks

Systematic Operations Risk-rating Tool

Risk Category	Rating at Approval	Previous Rating	Current Rating
Political and Governance	Low	Low	Low
Macroeconomic	Low	Moderate	Moderate
Sector Strategies and Policies	Moderate	Moderate	Moderate
Technical Design of Project or Program	Substantial	Substantial	Moderate
Institutional Capacity for Implementation and Sustainability	Moderate	Substantial	Substantial
Fiduciary	Moderate	Moderate	Moderate
Environment and Social	Low	Low	Low
Stakeholders	Low	Low	Low
Other	--	Moderate	Moderate
Overall	Substantial	Substantial	Substantial

Results

PDO Indicators by Objectives / Outcomes

To facilitate innovation in biopharma & medical devices addressing public health priorities in India				
▶ Number of products addressing public health priorities advanced at least one step on the product development pathway (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	19.00	50.00	6.00
Date	14-Nov-2016	04-Nov-2020	30-Apr-2021	01-May-2023
▶ Number of new IP registrations or product prototypes (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	32.00	39.00	15.00



Date	14-Nov-2016	04-Nov-2020	30-Apr-2021	01-May-2023
▶ Number of technologies licensed for manufacturing or commercialization (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	13.00	23.00	2.00
Date	14-Nov-2016	04-Nov-2020	30-Apr-2021	01-May-2023
▶ Number of TTOs established (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	5.00	7.00	6.00
Date	14-Nov-2017	04-Nov-2020	30-Apr-2021	01-May-2023
▶ Number of companies using shared facilities supported by the project (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	57.00	108.00	60.00
Date	14-Nov-2017	04-Nov-2020	30-Apr-2021	01-May-2023

Intermediate Results Indicators by Components

Strengthening the pilot-to market innovation ecosystem				
▶ Number of clinical trial sites that are GCP compliant (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	11.00	11.00	5.00
Date	14-Nov-2016	04-Nov-2020	30-Apr-2021	01-May-2023
▶ Number of registered technology transfer professionals qualified (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	15.00	25.00	12.00
Date	14-Nov-2016	04-Nov-2020	30-Apr-2021	01-May-2023
▶ Number of people trained (Number, Custom)				



	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	1,406.00	6,295.00	1,775.00
Date	14-Nov-2017	04-Nov-2020	30-Apr-2021	01-May-2023
□ Number of people trained who are women (Percentage, Custom Supplement)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	37.00	44.00	50.00

Accelerating the pilot-to-market process for specific products

▶ Number of product development agreements in place (Number, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	104.00	116.00	9.00
Date	14-Nov-2016	04-Nov-2020	30-Apr-2021	01-May-2023

▶ Number of international publications (Number, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	11.00	14.00	10.00
Date	14-Nov-2016	04-Nov-2020	30-Apr-2021	01-May-2023

▶ Proportion of grievances responded to and/or resolved within the stipulated service standards for response times (Percentage, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	100.00	90.00
Date	14-Nov-2016	04-Nov-2020	30-Apr-2021	01-May-2023

Comments: The PIU received five queries from respondents to issued RFPs seeking further detailed clarifications on the reasons of proposal rejections or further representations. All five were adequately responded to.

Performance-Based Conditions

Data on Financial Performance

Disbursements (by loan)

Project	Loan/Credit/TF	Status	Currency	Original	Revised	Cancelled	Disbursed	Undisbursed	% Disbursed
---------	----------------	--------	----------	----------	---------	-----------	-----------	-------------	-------------




P156241	IBRD-87510	Effective	USD	125.00	125.00	0.00	39.91	85.09	<div style="width: 32%; height: 15px; background-color: #28a745;"></div>	32%
---------	------------	-----------	-----	--------	--------	------	-------	-------	--------------------------------------------------------------------------	-----

Key Dates (by loan)

Project	Loan/Credit/TF	Status	Approval Date	Signing Date	Effectiveness Date	Orig. Closing Date	Rev. Closing Date
P156241	IBRD-87510	Effective	31-May-2017	24-Apr-2018	23-May-2018	30-Jun-2023	30-Jun-2023

Cumulative Disbursements



PBC Disbursement

PBC ID	PBC Type	Description	Coc	PBC Amount	Achievement Status	Disbursed amount in Coc	Disbursement % for PBC
--------	----------	-------------	-----	------------	--------------------	-------------------------	------------------------

Restructuring History

There has been no restructuring to date.

Related Project(s)

There are no related projects.